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Editorial on the Research Topic
Translational Insights Into Mechanisms and Therapy of Organ Dysfunction in Sepsis
and Trauma
Multiple organ dysfunction or even failure after sepsis or trauma is due to a dysregulated
host response. Currently, besides (surgical) source control (e.g., control of bleeding or drainage
of abscesses) and administration of antimicrobial drugs, therapeutic approaches are limited to
supportive care. Advances in our understanding of the key pathophysiological pathways involved
in the excessive inflammation triggered by trauma, sepsis and/or ischemia-reperfusion have had
limited impact. The 28 article in this Research Topic focus on the molecular mechanisms behind
(hyper) inflammation after sepsis or trauma, with special emphasis on preclinical and translational
studies that target potential organ-protective and/or -resuscitative therapeutic strategies. Most
studies report rodent models of trauma and elective surgery (three articles), non-microbial
hyper-inflammation induced with endotoxin exposure (LPS; seven articles) and chemical
pancreatitis (one article), and cecal ligation and puncture-induced sepsis (six articles). Additional
papers summarize investigations of human material (six articles) or fully-resuscitated large animal
models (two articles). These article are complimented by four reviews and a commentary.
RODENT MODELS OF TRAUMA AND (ELECTIVE)
SURGERY-RELATED TISSUE INJURY
Velagapudi et al. investigate the pathophysiology of post-traumatic/surgical delirium. The authors
investigated the effect of murine limb trauma on post-operative behavior (as assessed using
the 5- “choice serial reaction time task” and motor activity) and neuroinflammation and
blood-brain barrier integrity (by using light-sheet microscopy). Post-surgery behavior showed
impairment, in parallel with reduced microglial ramification and overall cell volume impaired
hippocampal astrocytic-tight junctions. Wall et al. characterized the mechanisms underlying
post-traumatic cardiac dysfunction in mice undergoing soft tissue trauma and bone fracture
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followed by hemorrhage. Despite resuscitation, stroke volume
remained at 25% of baseline values, which was associated
with leukocyte infiltration and ultrastructural sarcomere and
mitochondriadisorganization, leading to increased serum levels
of heart fatty acid-binding protein and troponin I. The authors
concluded that mitochondria-driven apoptosis may be a target
to prevent irreversible post-traumatic cardiac injury. In a rat
model of abdominal surgery, Bangash et al. further clarified the
anti-inflammatory properties of the β2-agonist dopexamine. Ileal
intravital microscopy demonstrated that attenuated leukocyte-
endothelial adhesion in post-capillary venules while neither
arteriolar diameter, functional capillary density nor systemic
hemodynamics nor lactic acidosis were affected compared to
control animals. Interestingly, despite comparable effects on
the intestinal microcirculation, high dose dopexamine only,
in contrast to the pure β2-agonist salbutamol, also attenuated
surgery-related increase in serum creatinine.
NON-MICROBIAL SYSTEMIC
HYPERINFLAMMATION
Although clearly distinct from polymicrobial sepsis, endotoxin
(LPS) challenge and chemically-induced pancreatitis are often
used tomodel hyperinflammation, and indeed, sepsis due to their
reproducibility and the subsequent organ failure that mimics
that of sepsis. Two studies addressed the potential role of the
glucocorticoid receptor (GR) in LPS-induced organ dysfunction.
Wepler et al. compared wildtype (GR+/+) mice with animals
with impaired GR dimerization (GRdim/dim) under conditions
of full intensive care support (“lung-protective” mechanical
ventilation, crystalloids, and norepinephrine). GRdim/dim mice
presented with more severe shock and aggravated acute
lung injury, which coincide with increased tissue osteopontin
expression. Ng et al. provided evidence for the anti-inflammatory
mechanisms of acute, binge-drinking-like alcohol intoxication:
alcohol exposure attenuated the inflammatory response to LPS
in vivo, ultimately improving survival, which was associated
with increased gene expression of the Glucocorticoid-Induced
Leucine Zipper (GILZ), a key molecule acting via non-canonical
GR activation. Inhibition of ethanol metabolism enhanced this
effect, and interestingly, the higher molecular-weight short-
chain alcohols propanol and isopropanol were even more potent
than ethanol.
Dayang et al. provided new evidence relating to the complex
organ- and organ- and microvascular bed-specific LPS-induced
expression of the endothelial adhesion molecules E-selectin
and VCAM-1. The authors showed in LPS-challenged mice
that the renal microvascular endothelium expressed various E-
selectin and VCAM-1 subpopulations, i.e., E-selectin−/VCAM-
1−, E-selectin+/VCAM-1−, E-selectin+/VCAM-1+, and E-
selectin−/VCAM-1+. The formation of subpopulations was a
common response of endothelial cells to LPS challenge. FACS
analysis demonstrated that the +/+ subpopulation expressed the
highest cytokine and chemokine response, which was mainly
TLR4-mediated. Activation of NF-κB and p38 MAPK were key
signaling events in the formation of this +/+subpopulation. The
translational value of these murine data was highlighted by
the recapitulation of these effects in LPS-exposed HUVEC and
human lung microvascular endothelial cells.
The role of the forebrain cholinergic system for the systemic
immune response was addressed by Lehner et al. The central-
acting cholinergic agonist galanthine suppressed the systemic
TNFα response to endotoxemia in mice, and this effect was
suppressed by both local genetic ablation of acetylcholine release
and vagotomy. In contrast, local and selective activation of
the M1 muscarinic acetylcholine receptor (M1 mAChR) with
the allosteric agonist benzyl quinolone carboxylic acid also
suppressed the serum TNFα levels, thereby ultimately improving
survival; these beneficial effects were again suppressed in M1
mAChR-ko mice. Overall, these data suggest a bidirectional
relationship between brain cholinergic signaling and the systemic
inflammatory response.
Two studies focussed on possible therapeutic interventions.
Deng et al. investigated the potential of targeting citrullinated
histone H3 (CitH3) to neutralize neutrophil extracellular traps.
When administered simultaneously with a lethal dose of LPS,
anti-CitH3 monoclonal antibodies prevented HUVEC damage
in vitro and attenuated ALI in vivo via inhibition of the
inflammatory response, thereby ultimately reducing mortality.
The therapeutic potential of the anti-inflammatory xanthone
glucoside mangiferin was studied by Yang et al. in mice with
LPS/galactosamine-induced acute liver failure. Pre-treatment
with magiferin inhibited hepatic TNF-α production, decreased
serum aminotransferase activities, and improved survival. This
beneficial effect was abolished by Kupffer cell deletion, and at
least in part, related to increased heme oxygenase-1 expression.
Models of caerulein-induced acute pancreatitis in vivo and
taurocholate-induced pancreatic acinar cell line in vitro were
used to study the roll of the Toll-like receptor 3 (TLR3) ligand
polyI:C by Huang et al. PolyI:C is a double-stranded RNA
mimic that can act as an immune stimulant by triggering
type I interferon (IFN) production and downstream IFN-
α/β receptor (IFNAR)-dependent signaling, and pre-treatment
inhibited chemotaxis and ROS production. This was abolished in
IFN-β- and IFNAR-ko mice.
CECAL LIGATION AND PUNCTURE
(CLP)-INDUCED SEPSIS
CLP is one of the most frequently used models of polymicrobial
sepsis. While three studies in this special issue were
designed to further character molecular pathways of sepsis
pathophysiology, others evaluated the efficacy of specific
therapeutic interventions. Most of the studies have the merit
of integrating the “Minimum Quality Threshold in Pre-Clinical
Sepsis Studies” (MQTiPSS) guidelines, thus allowing for easier
inter-laboratory comparability.
Li et al. addressed the role of the switch of macrophage
phenotype from the pro-inflammatory M1 state to the M2 repair
(i.e., resolution) state in septic AKI. Coculture of human M1
macrophages with proximal tubular (HK-2) cells revealed that
Colony Stimulating Factor 2 (Csf2) was the most up-regulated
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protein, and post-CLP injection of a Csf2 antibody attenuated
kidney M1-M2 macrophage transition via p-STAT5 signaling,
suppressed tubular proliferation, and increased mortality.
The role of AMP-activated protein kinase (AMPK) was
investigated in murine CLP-induced sepsis by Kikuchi et al.
Mice with genetic deletion of the catalytic α1 isoform (AMPKα1)
had higher systemic cytokine levels, liver and lung inflammation
and injury, and in particular, more severe hepatic mitochondrial
damage and mortality. These deleterious effects were even more
pronounced in male animals, suggesting that AMPK-dependent
liver metabolic (dys) function is sex-dependent.
Skiretzki et al. further characterized the translational value
of an established, “humanized” murine model of CLP-induced
sepsis. Animals were stratified as “predicted-to-die (P-DIE)” or
“predicted-to-survive (P-SUR),” and blood, bone marrow and
spleen were collected for cytokine and chemokines as well as
CD-80 and HLA-DR expression. TNFα, IL-6, IL-10, IL-8/KC-,
and MCP-1-levels were several-fold higher in the P-DIE group.
The study nicely showed that humanized mice reflect human
immune responses.
A possible therapeutic potential of the Bruton’s tyrosine
kinase (BTK) inhibitors ibrutinib and acalabrutinib for septic
cardiomyopathy and AKI was investigated by O’Riordan et al.
When administered early (1 h) after the CLP-procedure, the BTK
inhibitors attenuated sepsis-induced systolic dysfunction and
reduced systemic and tissue NF-κB and NLRP3 inflammasome
activation. This is clinically relevant as both BTK inhibitors
are already approved for the treatment of chronic lymphatic
leukemia (CLL), and acalabrutinib has recently been reported
to attenuate systemic inflammation in a small cohort of
patients with COVID-19 (Roschewski et al.). However, despite
promising data on ibrutinib during lipoteichoic acid-induced
pulmonary inflammation as well as and ceftriaxone-treated
pneumococcal pneumonia (1), a word of caution needs to be
mentioned concerning tyrosine kinase inhibitors in general:
the RESONATE-17 study on 144 CLL patients treated with
ibrutinib reported a 30% incidence of severe infection including
pneumonia (2), and in un-resuscitated CLP-induced murine
sepsis, the tyrosine kinase inhibitor dasatinib (administered as
a pre- and post-treatment) dose-dependently showed a “friend
or foe” profile: while low doses attenuated sepsis-related organ
dysfunction, and ultimately improved survival, high doses had
the opposite effect (3).
Another approved drug, the oral antidiabetic linagliptin, was
compared with the selective IkB kinase (IKK) inhibitor (IKK-
16), with respect to its effects on septic cardiomyopathy as
well as kidney and liver injury in murine high fat diet-induced
type 2 diabetes mellitus (T2DM) (Al Zoubi et al.). This study
is of particular importance, since it sheds light on one of the
most frequently occurring chronic co-morbidities observed in
patients with sepsis and/or after trauma, which is well-known
to worsen the patient’s outcome. In good agreement with these
clinical observations, T2DM aggravated sepsis-related (organ)
dysfunction associated with sepsis, which was comparably
mitigated by both tested drugs. This effect of linagliptin was
associated with reductions of NF-κB activation, iNOS expression
and serum levels of pro-inflammatory cytokines.
Finally, Janicova et al. characterized the role of uteroglobin
in a murine double-hit model of blunt chest trauma and
subsequent (24 h) CLP-induced sepsis focussing on dynamic
changes in monocyte and macrophage subsets. This double-
hit model has the possibility of replicating the frequently
occurring similar sequence in critically ill patients, i.e., an
initial polytrauma is complicated by consecutive sepsis, and
furthermore, allows investigating common “final routes” of these
two pathological entities. Both pro-inflammatory monocytes
and macrophages significantly increased in blood, lungs and
bronchoalveolar lavage fluid (BALF) at the expense of tissue
repairing macrophages, which coincided with higher levels of
TNF-α, MCP-1, and RAGE. Uteroglobin neutralization further
aggravated this pro-inflammatory response, and subsequently,
lung damage, thereby highlighting intrinsic anti-inflammatory
signaling role of this protein.
LARGE ANIMAL AND HUMAN STUDIES
Despite the substantial demand for personnel, infrastructure
and consumables as well as the often lacking test kits for the
species involved, large animal (in particular porcine) models
have the advantages (i) to allow for integration of standard ICU
procedures into the experimental design, and (ii) to study an
immunological environment that is closer to the human situation
than any other species (except for non-human primates). Horst
et al. made use of these facts for the characterization of
time-dependent dynamics of the inflammatory response in the
blood, the femur fracture hematoma, and muscle samples of
polytraumatized (“PT”: lung contusion, liver laceration, femur
fracture, and controlled hemorrhage) swine in comparison to
animals with femur fracture alone (monotrauma). The severity
of the polytrauma substantially inhibited the local generation
of proinflammatory and angiogenetic mediators, suggesting that
these systemic trauma-related changes of the local immunologic
milieu might explain the delayed bone repair in PT patients.
The same porcine PT model was used by Lackner et al. to
address the role of midkine levels for post-traumatic cardiac
dysfunction. The porcine data were complemented by (i) the
measurement of midkine blood levels in PT patients (ISS ≥
16), and (ii) the functional assessment of human cardiomyocytes
incubated with midkine. In PT patients, midkine levels were
several-fold higher than in healthy volunteers, while in vitro
midkine exposure of cardiomyocytes altered cell Ca2+ handling
and reduced maximum mitochondrial O2 consumption.
Sophisticated genome/transcriptome analyses were used by
Le et al. in two studies (Le, Matzaraki et al.; Le, Chu et al.)
that aimed at further characterizing the major determinants
of leukocyte and/or endothelium responses to bacterial sepsis.
In the first study (Le, Matzaraki et al.) expression quantitative
trait loci (eQTL) data from the largest whole-blood eQTL
database, cytokine QTLs from pathogen-stimulated peripheral
blood mononuclear cells (PBMC), blood transcriptome data
from pneumoniae-derived sepsis patients, and transcriptome
data from pathogen-stimulated PBMC were integrated and
found increased adherence-junction gene expression. The
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authors concluded that their approach provided evidence
for genetically determined variability in both leucocyte and
endothelial responses, which may contribute to explaining sepsis
heterogeneity. In their second study (Le, Chu et al.), the
authors’ group investigated transcriptomic responses of human
leukocytes and endothelial cells to Gram negative-bacteria,
Gram positive-bacteria, and fungi. While whole pathogen lysates
strongly activated leukocytes but not endothelial cells, the
mutual leukocyte response to pathogens resulted in endothelial
activation. Exposure of endothelial cells to leukocyte mediators
activated endothelial cells at both transcription and protein
levels, and revealed IL-1, TNF-α, and IFN as important drivers
of endothelial activation.
Another study was dedicated to investigate the potential
role of circadian rhythm and/or diurnal variations on the
systemic inflammatory response, and ultimately outcome in
patients with trauma (Zaaqoq et al.). From a total of nearly
500 blunt trauma survivors (ISS > 20) a subgroup of
patients injured during daytime (“mDay”) was compared to
patients injured at nighttime (“mNight”) in order to investigate
the impact on 32 inflammatory mediators using Dynamic
Network Analysis (DyNA) and Dynamic Bayesian Network
(DyBN) inference. Both hospital and ICU length of stay
were longer in the mNight patients, which coincided with
higher IL-17A but lower MIP-1α, IL-7, IL-15, GM-CSF, and
sST2 levels; DyBN yielded cortisol and sST2 as the major
upstream determinants upstream of TGF-β1, chemokines,
and Th17/protective mediators in both groups, with IL-
6 being an additional downstream node in the mNight
group only.
In patients with septic AKI undergoing continuous veno–
venous hemofiltration (CVVH),Wu et al. investigated the impact
of damage-associated molecular pattern (DAMP) (mitochondrial
DNA, mtDNA; nuclear DNA, nDNA; heat shock protein 70,
HSP70; high mobility group box 1, HMGB1) removal on
mortality. Both HSP70 and HMGB1 clearance rates were good
predictors of mortality, and high HSP70 clearance coincided with
the level of HLA-DR expression. Based on these findings the
authors cautioned the use of CVVH in AKI patients with sepsis
merely for the removal of inflammatory mediators in the absence
of any other indication for this therapeutic measure.
Finally, Neu et al. present a study on the feasibility
of a direct, non-invasive, bedside measurement of skin
mitochondrial oxygen tension (mitoPO2) with a new
commercially available device that makes use of the “in
vivo protoporphyrin IX-triplet state lifetime technique (PpIX-
TSLT).” In 40 patients a three-step measurement was
performed after enriching the clavipectoral triangle with 5-
aminolevulinic acid, which comprised assessment of baseline
values, evaluation of the effect of a local pressure to transitorily
stop microcirculatory blood flow, and a second control
value. The recorded data allowed calculating average and
maximum mitoVO2 at these three time points. The technique
was reproducible, easy, and safe; potential tissue edema as
assessed by bioimpedance resulted in lower mitochondrial
oxygen tension.
REVIEWS AND COMMENTARIES
Two articles reviewed potential new pathways (and consecutive
therapeutic targets) of sepsis-related immune paralysis. Cheng et
al. discuss the possible role of Parkinson disease protein 7 (Park
7), a well-established regulator of reactive oxygen species (ROS)
release through interaction with p47phox, a subunit of NADPH
oxidase. Among their various functions, ROS initiate TLR to
activate macrophages. Consequently, Park 7 may be a novel
therapeutic target to reverse sepsis-related immunosuppression.
Morrow et al. discuss septic immune paralysis in the light of
the markedly decreased T cell formation of pro-inflammatory
cytokines. Since targeting lymphocyte survival did not find its
way into clinical practice, cytokines with a more global immune
effect may represent alternative therapeutic targets. The authors
discuss the possible impact of the interleukin (IL)-17, IL-27, and
IL-33 based on data from patient serum and murine models of
peritonitis and pneumonia.
Denning et al. review the complex interplay of host response
to pathogens via interaction of pathogen-associated molecular
patterns (PAMPs) and pattern recognition receptors (PRRs) and
damage-associated molecular patterns (DAMPs), and Neutrophil
extracellular traps (NETs). Examples of DAMPs are extracellular
cold-inducible RNA-binding protein (eCIRP), high mobility
group box 1 (HMGB1), histones, and adenosine triphosphate
(ATP). DAMPs are released by inflammasome activation or
passively from dead cells. NETs aremixtures of extracellular DNA
with histones, myeloperoxidase, and elastase, all released during
inflammation. Although NETs clearly contribute to pathogen
clearance, their excessive formation causes tissue damage.
Based on their multiple and ubiquitous properties, Cheng et
al. discuss the potential of mesenchymal stem cells (MSCs) in
the treatment of sepsis. Highlighting the possible undesired side
effects, the authors also emphasize the potential of extracellular
vesicles (EVs) derived from MSCs (MSC-EVs). These MSC-
EVs appear to exert a therapeutic benefit similar to MSCs
in protecting against sepsis-induced organ dysfunction by
delivering RNAs and proteins to target cells, while at the same
time being devoid of major MSC side effects. In addition, MSC-
EVs provide some practical advantages over their parent MSCs.
Finally, Kesselmeier and Scherag comment on the recently
popularized “adaptive clinical trials” discussing a recent
article in this journal by Talisa et al. (4). The authors clearly
acknowledge that adaptive trials allow modifying design
elements during trial conduct, thereby possibly reducing
resources, duration and sample size while simultaneously
enhancing the chance of proof for an effective treatment.
Nevertheless, the authors discuss the four issues response
adaptive randomization (RAR), adaptive enrichment,
seamless, and platform designs, which need to be taken
into account.
In summary, the Research Topic entitled provides a broad and
detailed overview of new molecular and mechanistic avenues for
the management of sepsis- and trauma-related multiple organ
dysfunction, and represents a major contribution to translational
research in the field.
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